Korean J Dermatol.
2019 Jun;57(5):265-269.
Three Fibrotic Conditions Treated with 5% Topical Imiquimod Cream as an Antifibrotic Agent
- Affiliations
-
- 1Department of Dermatology, College of Medicine, Dong-A University, Busan, Korea. khkim@dau.ac.kr
Abstract
- Imiquimod, a toll-like receptor agonist, is a topical immunomodulator that induces the production of several cytokines including interferon-alpha, which shows antifibrotic properties. We hypothesized that the antifibrotic effect of imiquimod would soften fibrotic skin lesions. Therefore, we applied topical imiquimod with topical tacrolimus or systemic acitretin in patients with refractory lesions of myxedema, angiolymphoid hyperplasia, and generalized discoid lupus erythematosus and confirmed improvement in fibrotic lesions in these patients. Thus, we conclude that use of imiquimod improves fibrotic skin lesions. This report describes our experience with the treatment of this condition along with a review of the related literature.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A Case of Erythroplasia of Queyrat Treated with Imiquimod 5% Cream and Excision
- The Effect of 5% Imiquimod Cream on C57BL/6 Mouse Melanoma Growth
- Treatment of Keratoacanthoma with 5% Imiquimod Cream and Review of the Previous Report
- Topical Treatment with 5% Imiquimod for Solitary Keratoacanthoma
- 5% Imiquimod Cream in the Treatment of Bowen's Disease
